Verified Nov 2026
Other
·
Anderlecht, Brussels
·
Since 1928
UCB (Union Chimique Belge) is a Brussels-based biopharmaceutical company founded in 1928 that develops medicines for neurology, immunology, and rare diseases. Employing 10,000–50,000 people with annual revenue of €6 billion, the privately held firm invests over 25% of revenue into research and development. In 2026, UCB committed to building a biologics manufacturing campus in Georgia expected to create 330 permanent jobs.
UCB at a glance
Revenue
$5-10B
Est. band
Employees
10,000-50,000
Founded
1928
Headquarters
Anderlecht, Brussels
Certifications
ISO 14001
Import activity
10920
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
10920
Named foreign suppliers
50
Top origins
Republic of Korea · China · Singapore · Vietnam

Shared foreign counterparties do not establish that these companies buy from UCB.
What this tells a buyer
UCB processed over 10,900 shipments across supply chains originating primarily from Asia, including South Korea, China, Singapore, Vietnam, Malaysia, Taiwan, India, and Thailand.
The company manufactures medicines for epilepsy, Parkinson's disease, and rheumatoid arthritis, and holds ISO 14001 certification for environmental management.
UCB operates in over 40 countries and acquired Candid Therapeutics in 2026 to expand its immunology pipeline with T-cell engager technologies.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
98 years in operation (founded 1928).
10,920 US import shipments on record.
Holds ISO 14001 certification(s) per public sources.
Overview
UCB (Union Chimique Belge) is a Brussels-based biopharmaceutical company founded in 1928 that develops medicines for neurology, immunology, and rare diseases. Employing 10,000–50,000 people with annual revenue of €6 billion, the privately held firm invests over 25% of revenue into research and development. In 2026, UCB committed to building a biologics manufacturing campus in Georgia expected to create 330 permanent jobs.
At a glance
Attribute | Detail |
|---|---|
Founded | 1928 |
Headquarters | Anderlecht, Brussels |
Employees | 10,000-50,000 |
Revenue | $5-10B (estimated) |
Certifications | ISO 14001 |
What UCB makes
The company manufactures medicines for epilepsy, Parkinson's disease, and rheumatoid arthritis, and holds ISO 14001 certification for environmental management.
Certifications
UCB is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 14001 — novapharmanews.com
Trade and customs footprint
UCB processed over 10,900 shipments across supply chains originating primarily from Asia, including South Korea, China, Singapore, Vietnam, Malaysia, Taiwan, India, and Thailand. US customs bill-of-lading records list 10920 inbound shipments across 50 foreign suppliers, with top origins including Republic of Korea · China · Singapore · Vietnam.
Latest developments
2026-11-07 — UCB picks Veeva Vault CRM for worldwide engagement (marketscale.com)
2026-10-09 — UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia | UCB (ucb-usa.com)
2026-08-31 — UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing | UCB (ucb.com)
2026-05-03 — UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers | UCB (ucb.com)
2026-03-24 — UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs | UCB (ucb.com)
2026-03-03 — UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody | UCB (ucb.com)
Facilities
UCB is headquartered in Anderlecht, Brussels. Public sources also reference these locations:
Bulle, Switzerland — emerson.com
Brussels, Belgium — novapharmanews.com
Company details
UCB operates in over 40 countries and acquired Candid Therapeutics in 2026 to expand its immunology pipeline with T-cell engager technologies. UCB was founded in 1928, has an estimated 10,000-50,000 employees, and is headquartered in Anderlecht, Brussels. On the LightSource stability read it is rated "Established & active": 98 years in operation (founded 1928). 10,920 US import shipments on record. Holds ISO 14001 certification(s) per public sources.
Frequently asked questions
What does UCB do?
UCB (Union Chimique Belge) is a Brussels-based biopharmaceutical company founded in 1928 that develops medicines for neurology, immunology, and rare diseases. Employing 10,000–50,000 people with annual revenue of €6 billion, the privately held firm invests over 25% of revenue into research and development. In 2026, UCB committed to building a biologics manufacturing campus in Georgia expected to create 330 permanent jobs.
Where is UCB headquartered?
UCB is headquartered in Anderlecht, Brussels.
When was UCB founded?
UCB was founded in 1928.
How big is UCB?
UCB has an estimated 10,000-50,000 employees, with revenue in the $5-10B range (estimated).
What certifications does UCB hold?
UCB lists ISO 14001 on its website. Confirm the certified scope for the specific plant producing your part.
Does UCB import from overseas suppliers?
US customs bill-of-lading records show 10920 inbound shipments for UCB, with top origins including Republic of Korea · China · Singapore · Vietnam.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
